SIRNAOMICS Email Formats
Biotechnology Research • 
Germantown, Maryland, United States • 21-50 Employees
SIRNAOMICS Email Formats
SIRNAOMICS uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@sirnaomics.com), used 28.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@sirnaomics.com | 52.4% |
{first name}{last name} | johndoe@sirnaomics.com | 19% |
{first initial} | j@sirnaomics.com | 14.3% |
Key Contacts at SIRNAOMICS
Fai Poon
Chief Executive Officer
Randy Chen
Senior Director, Bioinformatics, China Cio
Martine Fotsing
Director Of Quality Assurance
Alice Zhang
Global Program Coordination/Operation Director, Assistance Treasury
Huijun Wei
Senior Director
Mamta Jha
Senior Director Clinical Operations
Patrick Lu
President And Ceo, Founder
Xudong Liao
Senior Director, Bioinformatics
Company overview
| Headquarters | 20511 Seneca Meadows Pkwy, 200, Germantown, Maryland 20876, US |
| Website | |
| NAICS | 541714 |
| Keywords | Biotech, Rare Diseases, Drug Development, Rnai |
| Founded | 2007 |
| Employees | 21-50 |
About SIRNAOMICS
Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Group's GalAhead™ mxRNA technology, is currently in Phase I development. STP125G is the second siRNA therapeutics based on Sirnaomics proprietary GalAhead™ mxRNA technology, targeting ApoC3 mRNA for cardiovascular disease treatment. STP237G is the first dual-targeted drug based on a GalAhead™ muRNA technology and is in the late stage of preclinical evaluation. The Group has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the expansion of the Group's clinical pipeline and establishment of the Group's manufacturing facility, Sirnaomics focuses on a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
SIRNAOMICS has 12 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore SIRNAOMICS's funding history, including investment rounds, total capital raised, and key backers.
SIRNAOMICS Tech Stack
Discover the technologies and tools that power SIRNAOMICS's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
Tag managers
Security
JavaScript libraries
UI frameworks
Analytics
Miscellaneous
JavaScript libraries
Recruitment & staffing
South Africa
Colombia
Spain
CanadaFrequently asked questions
4.8
40,000 users
